Lets hope, but we don't know the enrollment numbers and we're not likely to get them next week. If good, they may help the share price. Probably why we won't get them. Diluting at lower prices equates to more shares outstanding, and apparently that is a good thing.
I would say yes... from the low teens to spikes in clinical sites up and running at this time.... I'll consider the jump to the most recent 108 clinical sites part of the hockey stick enrollment and its not finished yet.
Its obvious to me that the BLA filing by BMS for Nivolumab being announced now for the 3rd quarter would be greatly diminished if Peregrine has enough data for a possible BLA filing of Bavituximab...